FDA approves Ketruda monotherapy in second-line cervical cancer for patients with PD-L1 expression ≥1%: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm This is an accelerated approval based on the single-arm KEYNOTE-158 study. (The PDUFA date was6/28/18.)